Teacher Retirement System of Texas Buys 2,088 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Teacher Retirement System of Texas grew its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 19.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,590 shares of the biotechnology company’s stock after buying an additional 2,088 shares during the period. Teacher Retirement System of Texas’ holdings in REGENXBIO were worth $97,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Barclays PLC increased its holdings in REGENXBIO by 141.3% during the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock worth $1,217,000 after acquiring an additional 67,948 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of REGENXBIO by 53.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after acquiring an additional 296,700 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of REGENXBIO by 602.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 17,533 shares during the last quarter. FMR LLC boosted its position in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,656 shares during the last quarter. Finally, Stifel Financial Corp grew its holdings in shares of REGENXBIO by 13.3% during the third quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock worth $1,566,000 after purchasing an additional 17,563 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Trading Up 4.3 %

Shares of REGENXBIO stock opened at $7.05 on Thursday. REGENXBIO Inc. has a 12-month low of $5.62 and a 12-month high of $20.77. The company has a market cap of $353.11 million, a P/E ratio of -1.40 and a beta of 1.26. The company’s fifty day simple moving average is $7.36 and its two-hundred day simple moving average is $8.65.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.26. The business had revenue of $21.21 million for the quarter, compared to analysts’ expectations of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research report on Tuesday, March 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. HC Wainwright decreased their price objective on REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, March 17th. Morgan Stanley upped their target price on REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, March 14th. Finally, The Goldman Sachs Group cut shares of REGENXBIO from a “buy” rating to a “neutral” rating and reduced their price target for the company from $38.00 to $14.00 in a research report on Tuesday, February 11th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, REGENXBIO has an average rating of “Moderate Buy” and a consensus target price of $32.78.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.